Author:
Alifirova V. M.,Kamenskikh E. M.,Koroleva E. S.,Kolokolova E. V.,Petrakovich A. M.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. All-Russian Society of Neurologists, Clinical Guidelines for Multiple Sclerosis (2019), https://www.ructrims.org/files/%D0%9A%D0%BB%D0%B8%D0%BD%20%D1%80%D0%B5%D0%BA%D0%A0%D0%A1_2019_3.docx, acc. Feb. 15, 2021.
2. N. Ghasemi, S. Razavi, and E. Nikzad, “Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy,” Cell J., 19, No. 1, 1–10 (2017), https://doi.org/10.22074/cellj.2016.4867.
3. Q. Wu, E. A. Mills, Q. Wang, et al., “Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis,” JCI Insight, 5, No. 3 (2020), https://doi.org/10.1172/jci.insight.134251.
4. T. Ziemssen, K. Akgün, and W. Brück, “Molecular biomarkers in multiple sclerosis,” J. Neuroinflamm., 16, No. 1, 272 (2019), https://doi.org/10.1186/s12974-019-1674-2.
5. R. Bergamaschi, C. Berzuini, A. Romani, and V. Cosi, “Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis,” J. Neurol. Sci., 189, No. 1–2, 13–21 (2001), https://doi.org/10.1016/S0022-510X(01)00572-X.